NCT03122457View on ClinicalTrials.gov

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Actinic Keratosis
Interventions
DRUG

lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination

At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03122457 - Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide | Biotech Hunter | Biotech Hunter